- Home
- SHPH vs QLGN Comparison
SHPH vs QLGN Comparison
Compare SHPH & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- QLGN
- Stock Information
- Founded
- SHPH 2012
- QLGN 1996
- Country
- SHPH United States
- QLGN United States
- Employees
- SHPH N/A
- QLGN N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SHPH Health Care
- QLGN Health Care
- Exchange
- SHPH Nasdaq
- QLGN Nasdaq
- Market Cap
- SHPH 3.2M
- QLGN 3.2M
- IPO Year
- SHPH 2022
- QLGN N/A
- Fundamental
- Price
- SHPH $0.84
- QLGN $4.07
- Analyst Decision
- SHPH
- QLGN
- Analyst Count
- SHPH 0
- QLGN 0
- Target Price
- SHPH N/A
- QLGN N/A
- AVG Volume (30 Days)
- SHPH 115.9K
- QLGN 20.7K
- Earning Date
- SHPH 11-13-2024
- QLGN 11-14-2024
- Dividend Yield
- SHPH N/A
- QLGN N/A
- EPS Growth
- SHPH N/A
- QLGN N/A
- EPS
- SHPH N/A
- QLGN N/A
- Revenue
- SHPH N/A
- QLGN N/A
- Revenue This Year
- SHPH N/A
- QLGN N/A
- Revenue Next Year
- SHPH N/A
- QLGN N/A
- P/E Ratio
- SHPH N/A
- QLGN N/A
- Revenue Growth
- SHPH N/A
- QLGN N/A
- 52 Week Low
- SHPH $0.58
- QLGN $3.34
- 52 Week High
- SHPH $4.94
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- SHPH 49.54
- QLGN 45.00
- Support Level
- SHPH $0.83
- QLGN $3.95
- Resistance Level
- SHPH $0.92
- QLGN $4.21
- Average True Range (ATR)
- SHPH 0.08
- QLGN 0.27
- MACD
- SHPH 0.01
- QLGN 0.00
- Stochastic Oscillator
- SHPH 51.97
- QLGN 22.08
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.